News from emd serono, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 27, 2016, 07:50 ET
Gary Zieziula

Gary Zieziula Appointed President and Managing Director of EMD Serono

 EMD Serono, the North America biopharma business of Merck KGaA, Darmstadt, Germany, announced today that Gary Zieziula has been appointed...

Jan 19, 2016, 09:00 ET
EMD Serono, Inc. Logo Cyan

EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US

EMD Serono, the biopharma business of Merck KGaA, Darmstadt, Germany today announced its continued commitment to serving the multiple sclerosis...

Nov 02, 2015, 09:00 ET

Merck KGaA, Darmstadt, Germany, Appoints Laszlo Radvanyi as Head of Global Immuno-Oncology Research

 Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the appointment of Laszlo Radvanyi, PhD, as Senior...

Oct 12, 2015, 14:40 ET

EMD Serono announces publication of PRISMS-15 yr follow-up study in patients using Rebif® (interferon beta-1a), focused on factors influencing outcomes in RRMS

 EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced that the Journal of Neurology,...

Oct 08, 2015, 15:00 ET

EMD Serono Announces Recipients of the Third Annual €1 Million Grant for Multiple Sclerosis Innovation

EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced the recipients of the third annual Grant for...

Oct 04, 2015, 11:01 ET

EMD Serono Announces Grant for Growth Innovation at ESPE in Barcelona

EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced the recipients of the Grant for Growth...

Sep 29, 2015, 09:14 ET
Joseph Leveque, M.D. U.S. Chief Medical Officer of EMD Serono

EMD Serono Advances Medical and Scientific Leadership and Entry into Oncology, Appointing Joseph Leveque, M.D. as U.S. Chief Medical Officer

 EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced today the appointment of Joseph Leveque, M.D. as...

Sep 29, 2015, 08:10 ET

EMD Serono Joins Industry Leaders for The Economist Events' War On Cancer Forum in Boston

EMD Serono today announced that Merck KGaA, Darmstadt, Germany, is a platinum sponsor of The Economist Events' Health Care Forum: War on Cancer....

Sep 28, 2015, 10:59 ET

EMD Serono Announces Pioneering Researchers Awarded with $1.1 Million Through Grant for Oncology Innovation Initiative

 EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced the winners of the 2015 Grant...

Sep 24, 2015, 09:36 ET

New Rebif® (interferon beta-1a) Data at ECTRIMS Highlights the Importance of Disability and Imaging Predictors for Long Term Outcomes

 EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced that data about Rebif® (interferon...

Sep 09, 2015, 09:40 ET

EMD Serono Appoints Scott Filosi as Senior Vice President of Managed Markets

 EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced today the appointment of Scott Filosi as Senior...

Jun 17, 2015, 08:00 ET

EMD Serono Announces EUR 1.2 million Grant for Fertility Innovation (GFI) for 2015 / 16

 EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced its strong support of the Grant...

Jun 08, 2015, 08:06 ET

Merck KGaA, Darmstadt, Germany, Illumina and Genea Form the Global Fertility Alliance for Excellence in Assisted Reproductive Treatment

 Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and...

May 28, 2015, 11:46 ET

Merck KGaA, Darmstadt, Germany, as Pioneer in Assisted Reproductive Treatments, Takes Leading Role in Fertility Technologies, Announces a Global Collaboration Agreement with Genea Biomedx

 Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and...

May 28, 2015, 08:12 ET
David Trexler, Senior Vice President of Oncology Commercial

EMD Serono Continues its Entry into Oncology with the Key Appointments of David Trexler to Senior Vice President of Oncology Commercial and Zhen Su, MD, MBA to Vice President of Medical Oncology

EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced two critical management appointments to lead its...

May 21, 2015, 09:00 ET
EMD Serono.

Rebif® (interferon beta-1a) Data at CMSC Annual Meeting Highlights Clinical and MRI Predictors for Long Term Outcomes

 EMD Serono, Inc., the U.S. biopharmaceuticals business of Merck KGaA, Darmstadt, Germany, announced today that data about...

May 15, 2015, 03:25 ET

Merck KGaA, Darmstadt, Germany to Present Data at ASCO That Illustrate How the Company is Tackling Difficult-to-Treat Cancers

ASCO Abstract # Avelumab*: 3023, 3044, 3055, TPS9386, TPS3101, 4042, 4047, 5509, 8034; evofosfamide: TPS9089, 8579; tepotinib: 2591;...

May 12, 2015, 06:25 ET

Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer

- Evofosfamide is an investigational compound currently in Phase III trials  - Advanced pancreatic cancer is second indication to...

May 06, 2015, 08:00 ET

EMD Serono Initiates Co-Promotion of XALKORI® (crizotinib) with Pfizer in the United States

 EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced it has begun co-promoting Pfizer's...

Apr 16, 2015, 09:26 ET
EMD Serono.

EMD Serono Highlights Scientific Commitment to MS with Data Presented at the AAN Annual Meeting

 EMD Serono, the U.S. biopharmaceuticals business of Merck KGaA, Darmstadt, Germany, announced today that data about Rebif® (interferon...